What is the latest market price of serputinib/serpatinib?

Selpercatinib is a highly selective RET kinase inhibitor that is widely used in patients with RET fusion or RET mutation-driven malignancies. RET abnormalities have been found in non-small cell lung cancer (NSCLC), thyroid cancer, and some other solid tumors. In the past, there was a lack of targeted therapeutic drugs, and patients' treatment options were relatively limited. Seputinib inhibits the abnormal activity of RET kinase, blocks downstream signaling pathways, such as RAS/MAPK and PI3K/AKT, inhibits tumor cell proliferation and migration, and induces apoptosis, thereby achieving precise targeted therapy.

In China, the original drug Seputinib is already on the market, but it has not yet been included in the medical insurance list, so the financial burden on patients is heavy. The commonly used specifications in China are 80mg and 56 capsules per box, and the price generally exceeds RMB 10,000. In overseas markets, the price difference between the European version and the American version of the original drug is obvious. The price per box ranges from 20,000 yuan to more than 100,000 yuan, which is affected by factors such as exchange rates, pricing systems, and procurement channels. In addition, generic drugs of Seputinib have been launched in some overseas regions. Their ingredients are basically the same as the original drug, and the price is even lower. For example, the price of a 40 mg 120-capsule generic drug produced by a Lao pharmaceutical factory is about more than 2,000 yuan per box, which significantly reduces the cost of medication for patients.

The market performance of Seputinib is not only driven by the efficacy of the drug itself, but is also closely related to medical insurance policies and testing penetration rates. For patients with RET-positive tumors, accurate molecular testing is a prerequisite for medication, which is also an important manifestation of the concept of precision medicine. With the gradual popularization of domestic genetic testing technology, more patients can clarify their RET status and choose suitable targeted drugs. In the future, as generic drugs are launched and medical insurance negotiations advance, the price of seputinib is expected to further decline, improving patient accessibility and promoting the clinical popularization of RET targeted therapy in China.

Reference:https://en.wikipedia.org/wiki/Selpercatinib